Showing results (831-840 of 5,688) with videos related to

Sort By:
Pageof 569
The Oncologist|July 25, 2013
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a reviewPavani Chalasani, Robert Livingston
The Oncologist|July 26, 2013
Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancerDavid D Chism, Michael E Woods, Matthew I Milowsky
The Oncologist|March 15, 2012
A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumorsRonan J Kelly, Robert W Robey, Clara C Chen, et al.
The Oncologist|March 20, 2012
Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature reviewJean-Baptiste Bachet, Lucie Peuvrel, Claude Bachmeyer, et al.
The Oncologist|February 29, 2012
Anthracycline regimen adherence in older patients with early breast cancerCarlos H Barcenas, Ning Zhang, Hui Zhao, et al.
The Oncologist|December 16, 2015
Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid PapulosisNadège Cordel, Benoît Tressières, Michel D'Incan, et al.
The Oncologist|February 26, 2016
Candidate Predictors of Health-Related Quality of Life of Colorectal Cancer Survivors: A Systematic ReviewMartijn J L Bours, Bernadette W A van der Linden, Renate M Winkels, et al.
The Oncologist|December 15, 2015
A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina ExperienceMegan J McKee, Kevin Keith, Allison M Deal, et al.
The Oncologist|December 15, 2015
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast CancerTakahiro Kogawa, Tamer M Fouad, Diane D Liu, et al.
The Oncologist|December 2, 2015
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseIordanis Gravanis, Kyriaki Tzogani, Paula van Hennik, et al.
Pageof 569